VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference

Rhea-AI Summary

VectivBio Holding AG (Nasdaq: VECT) announced that its CEO, Luca Santarelli, will join a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021, at 9:40 a.m. ET. The conversation will be accessible via a live webcast on the company’s website, with an archived replay available for 30 days. VectivBio focuses on treating severe rare conditions and is advancing its lead product, apraglutide, for short bowel syndrome with intestinal failure, alongside initiatives targeting inherited metabolic diseases.

BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11, 2021 at 9:40 a.m. ET.

A live webcast of the fireside chat will be accessible through the Events and Presentations section of VectivBio’s website at www.vectivbio.com. An archived replay of the webcast will be available for 30 days following the presentation.

About VectivBio AG

VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).

With the CoMET platform, we also aim to address severe and often fatal Inherited Metabolic Diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated Co-enzyme A (CoA) metabolism is a factor. Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies.

Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.

VectivBio Contacts:

Investors:
Investor Relations
ir@vectivbio.com

Media:
Morgan Warners
Finsbury Glover Hering
+1 (202) 295-0124
morgan.warners@fgh.com

FAQ

What time will VECT's CEO participate in the Credit Suisse Healthcare Conference?

Luca Santarelli will participate in the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021, at 9:40 a.m. ET.

How can I watch the VectivBio webcast from the conference?

The webcast will be available live on VectivBio's website under the Events and Presentations section.

What is VectivBio's lead product candidate?

VectivBio's lead product candidate is apraglutide, which is currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure.

What rare conditions does VectivBio aim to address?

VectivBio focuses on severe rare conditions, including gastrointestinal diseases and inherited metabolic diseases.

Where can I find more information about VectivBio?

More information can be found on VectivBio's official website at www.vectivbio.com.